Profile
Sergio Quezada was the founder of Achilles Therapeutics UK Ltd. (2016) and Achilles Therapeutics Plc (2020) where the title held was Chief Scientific Officer (2020-2025).
Dr. Quezada's current job is at University College London as Professor-Cancer Institute (2011-present).
Education history includes undergraduate studies at Pontificia Universidad Católica de Chile and a doctorate from Dartmouth Medical School.
Sergio Quezada active positions
| Companies | Position | Start |
|---|---|---|
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2011 |
Former positions of Sergio Quezada
| Companies | Position | End |
|---|---|---|
| ACHILLES THERAPEUTICS PLC | Founder | 01/02/2025 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer | Founder | - |
Training of Sergio Quezada
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pontificia Universidad Católica de Chile
Pontificia Universidad Católica de Chile Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dartmouth Medical School
Dartmouth Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer | Health Technology |
Achilles Therapeutics Plc
Achilles Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops and sells cancer immunotherapies | Health Technology |
- Stock Market
- Insiders
- Sergio Quezada
















